Suppliers and packagers for BELSOMRA

BELSOMRA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0005-13	1 BLISTER PACK in 1 CASE (0006-0005-13) / 3 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0005-30	3 CASE in 1 CARTON (0006-0005-30) / 1 BLISTER PACK in 1 CASE (0006-0005-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0033-13	1 BLISTER PACK in 1 CASE (0006-0033-13) / 3 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29

Belsomra (Suvorexant) Key Suppliers and Intellectual Property Landscape

Last updated: February 19, 2026

This report analyzes the key suppliers and intellectual property (IP) landscape for Belsomra (suvorexant), a dual orexin receptor antagonist approved for the treatment of insomnia. The analysis focuses on the manufacturing and supply chain, as well as patent protections, to inform R&D and investment decisions.

Who are the Primary Manufacturers of Belsomra's Active Pharmaceutical Ingredient (API)?

Merck & Co., Inc. (MSD outside the U.S. and Canada) is the primary developer and marketer of Belsomra. The company holds the New Drug Application (NDA) for suvorexant. API manufacturing is typically conducted by Merck or its contract manufacturing organizations (CMOs). Specific CMOs involved in the early-stage or commercial manufacturing of suvorexant API are not publicly disclosed due to confidentiality agreements. However, major pharmaceutical API manufacturers with capabilities in complex small molecule synthesis are likely partners.

These manufacturers must adhere to stringent Good Manufacturing Practice (GMP) regulations enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Key considerations for API suppliers include:

• Synthesis Expertise: The ability to synthesize suvorexant, which is a complex molecule, requires advanced organic chemistry expertise.
• Quality Control: Robust quality control systems are essential to ensure API purity, potency, and stability.
• Regulatory Compliance: All manufacturing processes must comply with global regulatory standards.
• Supply Chain Security: Ensuring a consistent and reliable supply of API is critical for uninterrupted drug production.
• Cost-Effectiveness: Competitive pricing is a factor, particularly as the drug approaches its patent expiration.

What are the Key Patents Protecting Belsomra (Suvorexant)?

Belsomra is protected by a portfolio of patents covering its composition of matter, methods of use, and manufacturing processes. The primary patent covering the compound itself is approaching expiration, opening the door for generic competition.

Composition of Matter Patents

The foundational patent for suvorexant is U.S. Patent No. 7,741,332, titled "Orexin Receptor Antagonists." This patent claims the chemical structure of suvorexant and related compounds.

• Issue Date: June 22, 2010
• Expiration Date: June 22, 2026 (with potential for extensions)

This patent is a critical component of Belsomra's IP protection. Its expiration date is a significant milestone for generic manufacturers.

Formulation and Method of Use Patents

In addition to the composition of matter patent, Merck holds patents related to specific formulations of suvorexant and methods of treating insomnia. These patents can extend market exclusivity beyond the core compound patent.

• U.S. Patent No. 8,278,324: Titled "Orexin Receptor Antagonists," this patent claims specific crystalline forms and formulations of suvorexant.

  • Issue Date: October 2, 2012
  • Expiration Date: October 2, 2029

• U.S. Patent No. 8,673,950: Titled "Orexin Receptor Antagonists," this patent also relates to crystalline forms and pharmaceutical compositions.

  • Issue Date: March 18, 2014
  • Expiration Date: March 18, 2031

• U.S. Patent No. 9,200,129: Titled "Methods of treating sleep disorders," this patent covers methods of using suvorexant for treating insomnia.

  • Issue Date: December 1, 2015
  • Expiration Date: December 1, 2030

These formulation and method of use patents could pose challenges for generic entrants attempting to launch bioequivalent products, depending on the specific claims and their enforceability.

Patent Term Extensions (PTEs) and Supplementary Protection Certificates (SPCs)

Merck has likely sought and obtained Patent Term Extensions (PTEs) in the U.S. and Supplementary Protection Certificates (SPCs) in Europe for Belsomra to compensate for regulatory review delays. These extensions can add several years of exclusivity to the underlying patents. The exact duration of these extensions varies by jurisdiction and the specific patent.

• PTE for U.S. Patent No. 7,741,332: Information regarding the specific PTE granted for this patent would be available through the U.S. Patent and Trademark Office (USPTO) database. PTEs are typically calculated based on the time spent in regulatory review.

SPCs in Europe provide patent-like protection for a period of up to five years beyond the nominal expiry of the basic patent, compensating for regulatory approval delays.

What is the Status of Belsomra's Market Exclusivity?

Belsomra received its initial FDA approval on October 13, 2014. This approval triggers various market exclusivity periods independent of patent protection.

• New Chemical Entity (NCE) Exclusivity: In the U.S., Belsomra benefits from 5 years of NCE exclusivity, which prevents the FDA from approving a generic version of the same active ingredient for any indication during this period. This period would have expired on October 13, 2019.

• Orphan Drug Exclusivity: Belsomra is not designated as an orphan drug, so this exclusivity does not apply.

• Pediatric Exclusivity: Merck may have received an additional 6 months of pediatric exclusivity by conducting studies in pediatric populations as required by the FDA. This would extend exclusivity beyond the NCE period.

The interplay between patent expiration dates and regulatory exclusivity periods determines the total period of market protection. With the primary composition of matter patent expiring in June 2026, and accounting for potential PTEs, the effective market exclusivity for Belsomra is primarily governed by the patent landscape.

Who are Potential Generic Manufacturers for Belsomra?

As Belsomra's key patents approach expiration, several generic pharmaceutical companies are likely preparing or have already filed Abbreviated New Drug Applications (ANDAs) with the FDA. These companies specialize in developing and manufacturing generic versions of branded drugs. Identifying specific generic competitors is challenging without direct market intelligence or review of pending ANDAs. However, companies with a strong track record in developing complex generics and a history of challenging innovator patents are likely candidates.

These companies typically focus on:

• API Sourcing: Establishing reliable and cost-effective sources for suvorexant API. This may involve contracting with independent API manufacturers or developing in-house synthesis capabilities.
• Formulation Development: Creating a generic formulation that is bioequivalent to Belsomra.
• Patent Litigation: Navigating the complex landscape of patent litigation, often seeking to invalidate or circumvent innovator patents.
• Regulatory Submission: Preparing and filing ANDAs with regulatory authorities.

The presence of Paragraph IV certifications in ANDAs, which assert that the relevant patents are invalid, unenforceable, or will not be infringed by the generic product, is a strong indicator of potential generic entry.

What are the Supply Chain Considerations for Belsomra?

The supply chain for Belsomra involves several critical stages, from API manufacturing to finished drug product.

API Manufacturing

As previously noted, Merck likely uses a combination of internal manufacturing and contract manufacturing organizations (CMOs) for suvorexant API production. Key considerations for this stage include:

• Global Sourcing: API can be sourced from various regions, with India and China being significant players in global API manufacturing due to cost advantages and established chemical synthesis infrastructure.
• Quality Assurance: Rigorous QA/QC protocols are essential at every step, from raw material sourcing to the final API.
• Regulatory Oversight: API manufacturers must comply with stringent cGMP regulations and are subject to inspections by regulatory agencies.

Drug Product Manufacturing

The finished dosage forms of Belsomra (tablets) are manufactured by Merck or its contracted pharmaceutical manufacturers. This involves:

• Formulation: Combining the suvorexant API with excipients (binders, fillers, disintegrants, lubricants) to create a stable and effective tablet.
• Tableting: Compressing the formulation into tablets of specific strengths.
• Packaging: Blister packing or bottling the tablets, followed by secondary packaging with labeling and patient information.

The supply chain for Belsomra's drug product is subject to the same regulatory scrutiny as API manufacturing. Any disruption in this chain, whether due to raw material shortages, manufacturing issues, or geopolitical events, can impact drug availability.

Distribution

The final stage involves distributing the finished Belsomra product to wholesalers, pharmacies, and healthcare providers. This requires:

• Cold Chain Management: If applicable, though suvorexant is typically stable at room temperature, proper storage conditions must be maintained.
• Logistics: Efficient transportation and inventory management systems.
• Track and Trace: Compliance with serialization and track-and-trace regulations to prevent counterfeiting and ensure product integrity.

What are the Market Trends Affecting Belsomra?

Several market trends influence the commercial outlook for Belsomra and the potential for generic entry.

Increasing Generic Competition in the Sleep Aid Market

The insomnia market is highly competitive, with a history of significant generic penetration once patents expire. The availability of multiple generic options typically leads to substantial price reductions.

Shift Towards Non-Benzodiazepine Hypnotics

Belsomra, as a dual orexin receptor antagonist, represents a newer class of insomnia medications compared to older benzodiazepines and Z-drugs. This class is generally perceived to have a lower risk of dependence and abuse, though safety profiles are still under scrutiny.

Pricing Pressures on Pharmaceuticals

Payers and governments worldwide are increasingly focused on controlling pharmaceutical costs. This pressure will likely intensify as Belsomra faces generic competition, leading to aggressive pricing strategies by generic manufacturers.

Regulatory Scrutiny of Sleep Medications

All medications for insomnia, regardless of class, face ongoing regulatory scrutiny regarding safety and efficacy. Post-marketing surveillance and potential label changes can impact a drug's market position.

Key Takeaways

• Merck & Co. (MSD) is the primary developer and marketer of Belsomra (suvorexant).
• The core composition of matter patent (U.S. Patent No. 7,741,332) for suvorexant expires on June 22, 2026, with potential extensions.
• Additional patents protect specific formulations and methods of use, potentially extending market exclusivity until 2030-2031.
• API manufacturing is likely handled by Merck or its undisclosed CMOs, adhering to strict GMP standards.
• Generic manufacturers are expected to enter the market following patent expirations, leading to increased price competition.
• The supply chain for Belsomra is complex, involving API production, drug product manufacturing, and distribution, all subject to regulatory oversight.

Frequently Asked Questions

1. When does the primary patent for Belsomra expire? The primary composition of matter patent for suvorexant, U.S. Patent No. 7,741,332, is scheduled to expire on June 22, 2026.

2. Can generic versions of Belsomra be launched before all patents expire? Generic manufacturers can attempt to launch products by challenging existing patents through Paragraph IV certifications in their ANDAs. If successful in invalidating or demonstrating non-infringement of key patents, they may achieve earlier market entry.

3. Who are the major API suppliers for suvorexant? Specific contract manufacturing organizations (CMOs) are not publicly disclosed by Merck. However, it is standard practice for major pharmaceutical companies to utilize global API manufacturers with advanced synthesis capabilities that adhere to stringent Good Manufacturing Practices (GMP).

4. What is the typical impact of generic entry on drug pricing for sleep aids? For insomnia medications, generic entry often leads to significant price erosion, with prices decreasing by 70% to 90% or more within the first year of multiple generic competitors entering the market.

5. Are there any other regulatory exclusivities that extend Belsomra's market protection beyond patents? Belsomra received 5 years of New Chemical Entity (NCE) exclusivity in the U.S. upon its initial approval in 2014, which expired in 2019. It may also have benefited from a 6-month pediatric exclusivity extension. These regulatory exclusivities are separate from patent protection.

Citations

[1] U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,741,332. Retrieved from USPTO Patent Full-Text and Image Database.

[2] U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,278,324. Retrieved from USPTO Patent Full-Text and Image Database.

[3] U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,673,950. Retrieved from USPTO Patent Full-Text and Image Database.

[4] U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,200,129. Retrieved from USPTO Patent Full-Text and Image Database.

[5] U.S. Food and Drug Administration. (2014, October 13). FDA approves Belsomra (suvorexant), a novel orexin receptor antagonist, for the treatment of insomnia. FDA News Release.